Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. Issue 8 (12th March 2021)

• Record Type: Journal Article
• Authors: Hunt, Adrian R; Nguyen, Vuong; Creuzot-Garcher, Catherine P; Alforja, Socorro; Gabrielle, Pierre-Henry; Zarranz-Ventura, Javier; Guillemin, Martin; Fraser-Bell, Samantha; Casaroli Marano, Ricardo P; Arnold, Jennifer; McAllister, Ian L; O'Toole, Louise; Gillies, Mark C; Barthelmes, Daniel; Mehta, Hemal
• Is Part Of: British journal of ophthalmology. Volume 106:Issue 8(2022)
• Page Start: 1178
• Page End: 1184
• Publication Date: 2021-03-12
• Subjects: macula -- retina -- treatment medical -- vision; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2020-318491
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Background/Aims: To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. Methods: A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion. Results: Generalised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively, p=0.59). The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (−170 (−153 to –187) µm vs −147 (−130 to –164) µm, respectively, p=0.001). The overall median (Q1, Q3) of 7 (4, 8) injections and 9 (7, 11) visits was similar between treatment groups. First grading of inactivity occurred sooner with aflibercept (p=0.01). Switching was more common from ranibizumab (37 eyes, 23%) than from aflibercept (17 eyes, 11%; p=0.002). Conclusion: Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.